EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma

Diana Berry, Dan Moldoveanu, Shivshankari Rajkumar, Mathieu Lajoie, Tiffany Lin, Daméhan Tchelougou, Samridhi Sakthivel, Itai Sharon, Antoine Bernard, Sandy Pelletier, Yael Ripstein, Alan Spatz und 18 weitere

Cell Reports · 2025-03 · 44 (3) · 115365

DOI: 10.1016/j.celrep.2025.115365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2025-03. Verfasst von Diana Berry und 29 weiteren Autor:innen. Beteiligte Einrichtung: Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC H3A 1A3, Canada; Department of Biochemistry, McGill University, Montréa…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Melanoma, Neurofibromin 1, Immune Evasion. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Institutes of Health Research, Canada Research Chairs Program, Canada Foundation for Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hotspot BRAF, hotspot NRAS, and NF1 loss-of-function mutations are found in approximately 50%, 25%, and 15% of cutaneous melanomas, respectively. Compared to mutant BRAF and NRAS, the role of NF1 loss in melanoma remains understudied. NF1 has a RAS GTPase-activating protein (GAP) function; however, studies also support NF1 RAS-independent tumor-suppressor functions. Recent reports indicate that patients with NF1 mutant melanoma have high response rates to anti-PD-1 immune checkpoint inhibitors (ICIs) for reasons that are not entirely clear. Here, we present data demonstrating that NF1 interacts with PD-L1. Furthermore, NF1 loss in melanoma lines increases PD-L1 cell surface expression through a RAS-GAP-independent mechanism. Co-culture experiments demonstrate that NF1 depletion in melanoma increases resistance to T cell killing, which can be abrogated with anti-PD-1/PD-L1 ICIs. These results support a model whereby NF1 loss leads to immune evasion through the PD-L1/PD-1 axis, providing support for the examination of anti-PD-1 therapies in other NF1 mutant cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenMelanomaNeurofibromin 1Immune EvasionTumor EscapeHumansCell Line, TumorImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

CP: CancerNF1PD-L1anti-PD-1cancerimmune checkpoint blockadeimmune checkpoint inhibitorsimmune evasionmelanomatumor suppressor

Substanzen

B7-H1 AntigenNeurofibromin 1CD274 protein, humanNF1 protein, humanImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC H3A 1A3, Canada; Department of Biochemistry, McGill University, Montréal, QC H3G 1Y6, Canada.
  • Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC H3A 1A3, Canada; McGill University Health Centre, Montréal, QC H4A 3J1, Canada.
  • Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC H3A 1A3, Canada.
  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) and Institut du cancer de Montréal, Montréal, QC H2X 0A9, Canada; Département de Médecine, Faculté de Médecine, Université de Montréal, Mont…
  • Department of Biochemistry, McGill University, Montréal, QC H3G 1Y6, Canada.
  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) and Institut du cancer de Montréal, Montréal, QC H2X 0A9, Canada.

Förderung

  • Canadian Institutes of Health Research
  • Canada Research Chairs Program
  • Canada Foundation for Innovation
  • University of Texas MD Anderson Cancer Center
  • Nature et technologies
  • Melanoma Research Alliance
  • Santé

Zitieren

APA

Berry, D., Moldoveanu, D., Rajkumar, S., Lajoie, M., Lin, T., Tchelougou, D., Sakthivel, S., Sharon, I., Bernard, A., Pelletier, S., Ripstein, Y., Spatz, A., Miller, W. H., Jamal, R., Lapointe, R., Mes-Masson, A. M., Petrecca, K., Meguerditchian, A. N., Richardson, K., …, & Watson, I. R. (2025). The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma. Cell Reports, 44(3), 115365. https://doi.org/10.1016/j.celrep.2025.115365

Vancouver

Berry D, Moldoveanu D, Rajkumar S, Lajoie M, Lin T, Tchelougou D, et al. The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma. Cell Reports. 2025;44(3):115365. doi:10.1016/j.celrep.2025.115365

BibTeX
@article{Berry2025,
  author = {Berry, Diana and Moldoveanu, Dan and Rajkumar, Shivshankari and Lajoie, Mathieu and Lin, Tiffany and Tchelougou, Daméhan and Sakthivel, Samridhi and Sharon, Itai and Bernard, Antoine and Pelletier, Sandy and Ripstein, Yael and Spatz, Alan and Miller, Wilson H and Jamal, Rahima and Lapointe, Réjean and Mes-Masson, Anne-Marie and Petrecca, Kevin and Meguerditchian, Ari-Nareg and Richardson, Keith and Wang, Beatrice and Chergui, May and Guiot, Marie-Christine and Watters, Kevin and Stagg, John and Schmeing, T Martin and Rodier, Francis and Turcotte, Simon and Mihalcioiu, Catalin and Meterissian, Sarkis and Watson, Ian R},
  title = {The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma},
  journal = {Cell Reports},
  year = {2025},
  volume = {44},
  number = {3},
  pages = {115365},
  doi = {10.1016/j.celrep.2025.115365}
}
Kostenlos starten →